FDA Advisers Consider Novavax COVID-19 Vaccine This Week - WebMD

The FDA’s vaccine advisors are scheduled to meet on Tuesday to consider authorizing the Novavax COVID-19 vaccine. The committee will vote on whether the benefits of the two-dose vaccine outweigh the risks for ages 18 and older.

In the FDA briefing document, the agency summarized that the known benefits among Novavax vaccine recipients relative to the placebo include a reduction in the risk of mild to severe COVID-19 occurri… [+1956 chars]

full article...